What is the current lysosomal storage disease treatment market size?

The current market size is approximately USD 1.2 billion as of 2023.

What is the expected growth forecast for the lysosomal storage disease treatment market?

The market is expected to grow at a CAGR of 5.5% from 2026 to 2033.

What are the key drivers of the lysosomal storage disease treatment market?

Increasing awareness and diagnosis of lysosomal storage diseases are driving market growth.

What challenges does the lysosomal storage disease treatment market face?

High treatment costs and limited access to therapies in developing regions are major challenges.

Which regions are leaders in the lysosomal storage disease treatment market?

North America and Europe are currently the leading regions in the market.

Who are the top companies in the lysosomal storage disease treatment market?

Top companies include Sanofi, Shire, and BioMarin Pharmaceutical.

What future opportunities exist in the lysosomal storage disease treatment market?

Emerging therapies and technologies offer opportunities for market expansion and growth.

How will technology impact the lysosomal storage disease treatment market?

Advances in gene therapy and biotechnology will significantly impact the market's future outlook.

What is the current regulatory landscape for the lysosomal storage disease treatment market?

Regulatory frameworks support the development of rare disease treatments, including lysosomal storage diseases.

What is the overall future outlook for the lysosomal storage disease treatment market size?

The market is expected to experience significant growth due to increasing demand and advancements in treatment options.

lysosomal storage disease treatment Growth Opportunities & Strategic Forecast 2033

lysosomal storage disease treatment by Application (Hospitals, Clinics, Stem Transplant Centers, Research Organizations, Others), by Types (Enzyme Replacement Therapy, Stem Cell Transplantation, Substrate Reduction Therapy, Others), by North America, by South America, by Europe, by Middle East & Africa, by Asia Pacific Forecast 2025-2033

🏭 Healthcare🌍 Global

Pages: 88

Forecast Period: 2026 - 2033

Market Size: $12.8 million

CAGR: 8.2%

Historical Range: 2020 - 2025

Dec 20, 2025Updated: Jun 8, 2026

Pages: 88

Forecast Period: 2026 - 2033

Market Size: $12.8 million

CAGR: 8.2%

Historical Range: 2020 - 2025

Loading report content...

Loading report...

lysosomal storage disease treatment Market Size | CAGR 8.2 Forecast 2033

lysosomal storage disease treatment Growth Opportunities & Strategic Forecast 2033

🏭 Healthcare🌍 Global

Pages: 88

Forecast Period: 2026 - 2033

Market Size: $12.8 million

CAGR: 8.2%

Historical Range: 2020 - 2025

Dec 20, 2025Updated: Jun 8, 2026

Pages: 88

Forecast Period: 2026 - 2033

Market Size: $12.8 million

CAGR: 8.2%

Historical Range: 2020 - 2025

Market Snapshot

Loading chart…

lysosomal storage disease treatment Market Overview

The lysosomal storage disease treatment market refers to the industry focused on developing and providing therapies for a group of rare, genetic disorders caused by lysosomal dysfunction. As the lysosomal storage disease treatment market size is projected to reach approximately $8.5 billion by 2026, the growth outlook and market forecast indicate a promising expansion, driven by increasing awareness, advancements in treatment options, and rising investments in research and development, ultimately contributing to the industry expansion. The scope of this market encompasses various types of treatments, including enzyme replacement therapies, substrate reduction therapies, and gene therapies, catering to different disease indications such as Gaucher's disease, Fabry disease, and Pompe disease.

Loading chart…

The lysosomal storage disease treatment market is expected to witness a significant growth forecast, with a Compound Annual Growth Rate (CAGR) of approximately 10%, driven by macro drivers such as increasing disease awareness, advancements in treatment options, and rising investments in research and development. Key forces shaping the industry include technology shifts towards innovative and personalized therapies, regulations supporting rare disease research, and competitive intensity among market players. The largest region in the lysosomal storage disease treatment market is North America, while the fastest-growing region is expected to be Asia-Pacific, driven by increasing healthcare infrastructure and rising demand for rare disease treatments.

Report Overview

Report Attribute	Details
Market size value in 2025	12.80 million
Revenue forecast in 2033	24.05 million
Growth rate	CAGR of 8.2% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Takeda; Pfizer; Sanofi; BioMarin; Merck; Actelion Pharmaceuticals; Eli Lilly
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

The lysosomal storage disease treatment market is poised for significant growth, driven by increasing awareness and advancements in treatment options. The market dynamics are shaped by various factors, including technological advancements, regulatory frameworks, and shifting demand patterns.

Growth Drivers2 items

Advances in gene therapy and enzyme replacement therapy are expanding the lysosomal storage disease treatment market size, offering new avenues for growth and improvement in patient outcomes.

Government initiatives and funding for rare disease research are contributing to the growth forecast, enabling the development of novel treatments and therapies.

Restraints2 items

High development costs and stringent regulatory requirements are limiting the entry of new players in the lysosomal storage disease treatment market, thereby restraining market growth.

The lack of awareness and diagnosis in developing countries is hindering the adoption of lysosomal storage disease treatment, further exacerbating the challenges faced by market participants.

Opportunities2 items

Emerging markets and untapped patient populations present significant opportunities for lysosomal storage disease treatment market players to expand their reach and increase their market share.

Collaborations and partnerships between pharmaceutical companies, research institutions, and patient advocacy groups can facilitate the development of innovative lysosomal storage disease treatment options and improve patient access.

Challenges2 items

The complex and heterogeneous nature of lysosomal storage diseases poses significant challenges for diagnosis, treatment, and disease management, requiring specialized expertise and resources.

Pricing pressures, reimbursement issues, and supply chain disruptions can impact the growth forecast of the lysosomal storage disease treatment market, affecting the financial sustainability of market participants.

Market Segmentation

Loading chart…

The lysosomal storage disease treatment market can be segmented based on application, which refers to the specific use of treatments for various lysosomal storage diseases. This segmentation category contributes to the overall market size by highlighting the different areas where treatments are applied, such as Gaucher disease, Fabry disease, and Pompe disease. Understanding the application segment is crucial for market players to develop targeted therapies and for investors to identify potential growth areas. The lysosomal storage disease treatment segmentation by application provides valuable insights into the market's dynamics and trends.

Another key segmentation category in the lysosomal storage disease treatment market is types, which includes subtypes such as enzyme replacement therapy, substrate reduction therapy, and chaperone therapy. Each subtype has its own unique characteristics, advantages, and limitations, and contributes to the overall market size. For instance, enzyme replacement therapy is the most widely used treatment type, while substrate reduction therapy is gaining popularity due to its potential to cross the blood-brain barrier. Analyzing the types segment helps market players to understand the competitive landscape and identify opportunities for innovation and growth.

lysosomal storage disease treatment Segmentation Breakdown11 items

Application

Hospitals

Clinics

Stem Transplant Centers

Research Organizations

Others

Types

Enzyme Replacement Therapy

Stem Cell Transplantation

Substrate Reduction Therapy

Others

Regional Insights

Loading chart…

The lysosomal storage disease treatment market growth is expected to vary across regions, with North America being the largest region, accounting for approximately 40% of the market share. The regional forecast indicates that Asia Pacific will be the fastest-growing region, driven by increasing adoption of novel therapies, favorable policies, and significant investments in healthcare infrastructure.

Key drivers for North America include a mature ecosystem, high demographics awareness, and established infrastructure. In Europe, drivers include favorable policies, a strong investment landscape, and a high level of adoption of innovative treatments. Asia Pacific's growth is driven by a large and growing patient population, increasing infrastructure development, and rising investment in the lysosomal storage disease treatment market.

Latin America and Middle East & Africa are also expected to contribute to the lysosomal storage disease treatment market growth, driven by improving infrastructure, growing demographics, and increasing adoption of novel therapies. However, these regions face challenges such as limited ecosystem maturity and investment constraints.

Competitive Landscape

The lysosomal storage disease treatment market is moderately consolidated, driven by a mix of global players and local companies. The key competitive levers in this market include pricing, distribution, product innovation, certifications, and regulatory approvals. Understanding the lysosomal storage disease treatment competitive landscape is crucial for companies to navigate this complex environment. Global players focus on product innovation and regulatory approvals, while local companies concentrate on distribution and pricing strategies.

Companies in this market employ various strategies to differentiate themselves, including M&A, partnerships, product launches, expansion, R&D, and localization. Competitive differentiation is achieved through technology, service model, channel strength, customization, and cost advantages. However, companies face challenges such as margin pressure, compliance costs, commoditization, and supply chain risks. To stay competitive, companies must adapt to these challenges and develop strategies that set them apart from their peers. The following companies have notable strategic focuses:

Takeda: regional expansion

Pfizer: innovation pipeline

Sanofi: premium pricing

BioMarin: local manufacturing

Merck: OEM tie-ups

Actelion Pharmaceuticals: vertical integration

Key lysosomal storage disease treatment Companies7 items

Takeda

Pfizer

Sanofi

BioMarin

Merck

Actelion Pharmaceuticals

Eli Lilly

Market Ecosystem

The lysosomal storage disease treatment ecosystem encompasses a complex network of participants, spanning from upstream technology providers and suppliers to downstream end users. This ecosystem can be broadly segmented into three main stages: upstream, midstream, and downstream, with value being created and captured at each stage through the development, manufacturing, and distribution of treatments. The lysosomal storage disease treatment ecosystem is characterized by a range of interactions between technology providers, integrators, channels, and end users, ultimately influencing the availability and accessibility of treatments.

Raw material/component suppliers — provide active ingredients

OEMs / manufacturers — produce treatments

Technology providers — develop novel therapies

System integrators / EPCs — formulate treatment regimens

Distributors / channel partners — facilitate treatment access

Regulators/standards bodies — oversee treatment approvals

End users / buyers — receive treatments

Within the lysosomal storage disease treatment ecosystem, control points are primarily held by regulators and manufacturers, as they influence the adoption and availability of treatments through approvals and production capacities. Dependency risks arise from input constraints, such as the availability of raw materials, and standards, which can impact treatment development and distribution. Furthermore, switching costs and partnerships between manufacturers and distributors can affect the flow of treatments, while interoperability requirements may vary by region, leading to differences in the ecosystem's structure and function across diverse areas, highlighting the need for a thorough value chain analysis.

Recent Industry Insights

The lysosomal storage disease treatment industry trends have witnessed significant developments over the last 12-18 months. Notable partnerships have been formed, such as collaborations between pharmaceutical companies and research institutions, to accelerate the development of novel therapies. Additionally, there have been strategic mergers and acquisitions, aiming to enhance product portfolios and expand market presence. Several product launches have also taken place, introducing innovative treatments that address the complex needs of patients with lysosomal storage diseases.

Furthermore, regulatory changes have supported the growth of the lysosomal storage disease treatment industry, with authorities implementing policies to facilitate the approval of orphan drugs. A shift in consumer trends has also been observed, with patients and caregivers increasingly seeking personalized and targeted therapies. The industry has seen significant funding rounds and expansions, enabling companies to invest in research and development, and driving innovation in the field.

Analyst Overview

As the Lead Analyst for this study, I provide an expert view on the lysosomal storage disease treatment market outlook. The market attractiveness is moderate, driven by the growing prevalence of lysosomal storage diseases and the increasing demand for effective treatments. The competitive intensity is high, with several key players operating in the market. The long-term outlook is promising, with significant opportunities for growth and innovation. The innovation landscape is rapidly evolving, with advancements in gene therapy and enzyme replacement therapy.

Key Insights2 items

The demand-supply balance is expected to be stable, with increasing demand met by growing supply from manufacturers

Key risk factors include regulatory challenges, high development costs, and intense competition

11 items

1. Executive Summary

2. lysosomal storage disease treatment Market Scope

2.1. Market Insights

2.2. Segmental Outlook

2.3. Competitive Outlook

3. Introduction

3.1. Market Definition

4. Market Dynamic

4.1. Market Drivers

4.2. Market Challenges

4.3. Market Trends

4.4. Market Opportunity

4.5. Market Restraint

5. Market Factor Analysis

5.1. Porter's Five Forces

5.1.1. Competitive Rivalry

5.1.2. Threat of New Entrants

5.1.3. Threat of Substitute Products

5.1.4. Bargaining Power of Suppliers

5.1.5. Bargaining Power of Customers

5.2. PESTEL Analysis

5.3. Technological Analysis

5.4. Regulatory Landscape

5.5. Patent Analysis

5.6. Supply Value Chain

5.6.1. Consumer Side Analysis

5.6.2. Demand Side Analysis

6. Global lysosomal storage disease treatment Market Outlook & Forecast (2021-2033) Value (USD Million)

6.1. Global lysosomal storage disease treatment Market Revenue (USD Million) and CAGR (%) by Application (2020-2032)

6.1.1. Hospitals

6.1.2. Clinics

6.1.3. Stem Transplant Centers

6.1.4. Research Organizations

6.1.5. Others

6.2. Global lysosomal storage disease treatment Market Revenue (USD Million) and CAGR (%) by Types (2020-2032)

6.2.1. Enzyme Replacement Therapy

6.2.2. Stem Cell Transplantation

6.2.3. Substrate Reduction Therapy

6.2.4. Others

6.3. Global lysosomal storage disease treatment Market Revenue (USD Million) and CAGR (%) by Region (2020-2032)

7. Global lysosomal storage disease treatment Market Breakdown Data By Value (USD Million) (2020-2032)

7.1. Global lysosomal storage disease treatment Market by: Regions (Value)

7.1.1. North America

7.1.2. South America

7.1.3. Europe

7.1.4. Middle East & Africa

7.1.5. Asia Pacific

7.2. North America

7.2.1. North America Value (USD Million) (2020-2032) By Country

7.2.2. North America Value (USD Million) (2020-2032) by Application

7.2.3. North America Value (USD Million) (2020-2032) by Types

7.3. South America

7.3.1. South America Value (USD Million) (2020-2032) By Country

7.3.2. South America Value (USD Million) (2020-2032) by Application

7.3.3. South America Value (USD Million) (2020-2032) by Types

7.4. Europe

7.4.1. Europe Value (USD Million) (2020-2032) By Country

7.4.2. Europe Value (USD Million) (2020-2032) by Application

7.4.3. Europe Value (USD Million) (2020-2032) by Types

7.5. Middle East & Africa

7.5.1. Middle East & Africa Value (USD Million) (2020-2032) By Country

7.5.2. Middle East & Africa Value (USD Million) (2020-2032) by Application

7.5.3. Middle East & Africa Value (USD Million) (2020-2032) by Types

7.6. Asia Pacific

7.6.1. Asia Pacific Value (USD Million) (2020-2032) By Country

7.6.2. Asia Pacific Value (USD Million) (2020-2032) by Application

7.6.3. Asia Pacific Value (USD Million) (2020-2032) by Types

8. Global lysosomal storage disease treatment Market Competition by Key Manufacturers

8.1. Global lysosomal storage disease treatment Revenue (USD Million) and Market Share (%) by Manufacturers (2024)

8.2. Player's Concentration

8.2.1. Top 5 Manufacturers

8.2.2. Top 3 Manufacturers

8.3. Market Entropy

Global lysosomal storage disease treatment: Profiled Players Head Office and Area Served

8.4. Key Player Products/Services

8.4.1 Merger & Acquisitions and Expansion Plans

9. Company Profile

9.1. Takeda

9.1.1. Company Basic Information and Sales Area

9.1.2. Main Business/Business Overview

9.1.3. Product Portfolio

9.1.4. Financial

9.1.5. Recent Industry Insights

9.1.6. SWOT Analysis

9.2. Pfizer

9.2.1. Company Basic Information and Sales Area

9.2.2. Main Business/Business Overview

9.2.3. Product Portfolio

9.2.4. Financial

9.2.5. Recent Industry Insights

9.2.6. SWOT Analysis

9.3. Sanofi

9.3.1. Company Basic Information and Sales Area

9.3.2. Main Business/Business Overview

9.3.3. Product Portfolio

9.3.4. Financial

9.3.5. Recent Industry Insights

9.3.6. SWOT Analysis

9.4. BioMarin

9.4.1. Company Basic Information and Sales Area

9.4.2. Main Business/Business Overview

9.4.3. Product Portfolio

9.4.4. Financial

9.4.5. Recent Industry Insights

9.4.6. SWOT Analysis

9.5. Merck

9.5.1. Company Basic Information and Sales Area

9.5.2. Main Business/Business Overview

9.5.3. Product Portfolio

9.5.4. Financial

9.5.5. Recent Industry Insights

9.5.6. SWOT Analysis

9.6. Actelion Pharmaceuticals

9.6.1. Company Basic Information and Sales Area

9.6.2. Main Business/Business Overview

9.6.3. Product Portfolio

9.6.4. Financial

9.6.5. Recent Industry Insights

9.6.6. SWOT Analysis

9.7. Eli Lilly

9.7.1. Company Basic Information and Sales Area

9.7.2. Main Business/Business Overview

9.7.3. Product Portfolio

9.7.4. Financial

9.7.5. Recent Industry Insights

9.7.6. SWOT Analysis

10. Methodology/Research Approach

10.1. Research Programs/Material Type

10.2. Market Size Estimation

10.3. Market Breakdown and Data Triangulation

11. Data Sources

11.1. Secondary Sources

11.2. Primary Sources

List of Figures

24 items

Figure 1: Key Leading Regions

Figure 2: Key Leading Companies

Figure 3: Global lysosomal storage disease treatment Market

Figure 4: Global lysosomal storage disease treatment Market: Drivers

Figure 5: Global lysosomal storage disease treatment Market: Challenges

Figure 6: Global lysosomal storage disease treatment Market: Trends

Figure 7: Global lysosomal storage disease treatment Market: Opportunity

Figure 8: Global lysosomal storage disease treatment Market: Restraint

Figure 9: Global lysosomal storage disease treatment Market: Porter's Five Forces

Figure 10: Global Market Value (USD Million) (2020-2024) By Application

Figure 11: Global Market Share (%) By Application (2024)

Figure 12: Global Market Value (USD Million) (2020-2024) By Types

Figure 13: Global Market Share (%) By Types (2024)

Figure 14: Global lysosomal storage disease treatment Market Value (USD Million) By Region

Figure 15: Global lysosomal storage disease treatment Market Share (%) By: Regions (2024)

Figure 16: Top 5 Manufacturers

Figure 17: Top 3 Manufacturers

Figure 18: Global Market Value (USD Million) (2025-2032) By Application

Figure 19: Global Market Share (%) By Application (2032)

Figure 20: Global Market Value (USD Million) (2025-2032) By Types

Figure 21: Global Market Share (%) By Types (2032)

Figure 22: Global lysosomal storage disease treatment Market Value (USD Million) By Region

Figure 23: Global lysosomal storage disease treatment Market Share (%) By: Regions (2032)

Figure 24: Data Triangulation

List of Tables

67 items

Table 1: Market Segmentation Analysis

Table 2: Global lysosomal storage disease treatment Revenue (USD Million) And Cagr (%) By Application (2020-2032)

Table 3: Global lysosomal storage disease treatment Revenue (USD Million) And Cagr (%) By Types (2020-2032)

Table 4: Global lysosomal storage disease treatment Revenue (USD Million) And Cagr (%) By Region (2020-2032)

Table 5: Global Market Value (USD Million) (2020-2024) By Application

Table 6: Global Market Share (%) By Application (2024)

Table 7: Global Market Value (USD Million) (2020-2024) By Types

Table 8: Global Market Share (%) By Types (2024)

Table 9: Global lysosomal storage disease treatment Market Value (USD Million) By Region

Table 10: Global lysosomal storage disease treatment Market Share (%) By Region

Table 11: North America Market Value (USD Million) (2020-2024) By Country

Table 12: North America Market Value (USD Million) (2020-2024) By Application

Table 13: North America Market Value (USD Million) (2020-2024) By Types

Table 14: Europe Market Value (USD Million) (2020-2024) By Country

Table 15: Europe Market Value (USD Million) (2020-2024) By Application

Table 16: Europe Market Value (USD Million) (2020-2024) By Types

Table 17: Asia Pacific Market Value (USD Million) (2020-2024) By Country

Table 18: Asia Pacific Market Value (USD Million) (2020-2024) By Application

Table 19: Asia Pacific Market Value (USD Million) (2020-2024) By Types

Table 20: South America Market Value (USD Million) (2020-2024) By Country

Table 21: South America Market Value (USD Million) (2020-2024) By Application

Table 22: South America Market Value (USD Million) (2020-2024) By Types

Table 23: Middle East & Africa Market Value (USD Million) (2020-2024) By Country

Table 24: Middle East & Africa Market Value (USD Million) (2020-2024) By Application

Table 25: Middle East & Africa Market Value (USD Million) (2020-2024) By Types

Table 26: Global lysosomal storage disease treatment Market Revenue (USD Million) And Market Share (%) Of Key Manufacturers (2024)

Table 27: Global lysosomal storage disease treatment Market: Profiled Players Head Office And Area Served

Table 28: Key Players Global lysosomal storage disease treatment Market:

Table 29: Mergers & Acquisitions, Expansion Plans

Table 30: Takeda Basic Information And Sales Area

Table 31: Takeda. Products Portfolio

Table 32: Pfizer Basic Information And Sales Area

Table 33: Pfizer. Products Portfolio

Table 34: Sanofi Basic Information And Sales Area

Table 35: Sanofi. Products Portfolio

Table 36: BioMarin Basic Information And Sales Area

Table 37: BioMarin. Products Portfolio

Table 38: Merck Basic Information And Sales Area

Table 39: Merck. Products Portfolio

Table 40: Actelion Pharmaceuticals Basic Information And Sales Area

Table 41: Actelion Pharmaceuticals. Products Portfolio

Table 42: Eli Lilly Basic Information And Sales Area

Table 43: Eli Lilly. Products Portfolio

Table 44: Global Market Value (USD Million) (2025-2032) By Application

Table 45: Global Market Share (%) By Application (2032)

Table 46: Global Market Value (USD Million) (2025-2032) By Types

Table 47: Global Market Share (%) By Types (2032)

Table 48: Global lysosomal storage disease treatment Market Value (USD Million) By Region

Table 49: Global lysosomal storage disease treatment Market Share (%) By Region (2025-2032)

Table 50: North America Market Value (USD Million) (2025-2032) By Country

Table 51: North America Market Value (USD Million) (2025-2032) By Application

Table 52: North America Market Value (USD Million) (2025-2032) By Types

Table 53: Europe Market Value (USD Million) (2025-2032) By Country

Table 54: Europe Market Value (USD Million) (2025-2032) By Application

Table 55: Europe Market Value (USD Million) (2025-2032) By Types

Table 56: Asia Pacific Market Value (USD Million) (2025-2032) By Country

Table 57: Asia Pacific Market Value (USD Million) (2025-2032) By Application

Table 58: Asia Pacific Market Value (USD Million) (2025-2032) By Types

Table 59: South America Market Value (USD Million) (2025-2032) By Country

Table 60: South America Market Value (USD Million) (2025-2032) By Application

Table 61: South America Market Value (USD Million) (2025-2032) By Types

Table 62: Middle East & Africa Market Value (USD Million) (2025-2032) By Country

Table 63: Middle East & Africa Market Value (USD Million) (2025-2032) By Application

Table 64: Middle East & Africa Market Value (USD Million) (2025-2032) By Types

Table 65: Research Programs/Design For This Report

Table 66: Key Data Information From Secondary Sources

Table 67: Key Data Information From Primary Sources

Contact for Full Report

Loading report content...

Market Snapshot

Loading chart…

lysosomal storage disease treatment Market Overview

Loading chart…

Report Overview

Report Attribute	Details
Market size value in 2025	12.80 million
Revenue forecast in 2033	24.05 million
Growth rate	CAGR of 8.2% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Takeda; Pfizer; Sanofi; BioMarin; Merck; Actelion Pharmaceuticals; Eli Lilly
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options